New EMA conflicts of interests policy could curtail patient expert advice, says EFPIA
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is toughening its conflicts of interests policy to further ensure that its scientific experts do not have links to the pharmaceutical industry that affect their impartiality. However, the industry is concerned that a lack of clarity in the new policy may end up in a shortage of patient experts who are able to "feedback" to either the agency or pharmaceutical companies.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.